Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Part of paid clinical trials in Beverly Hills, California.

Sponsor
Iconic Therapeutics, Inc.
Study ID
NCT03452527
Phase
PHASE2
Status
Terminated

Conditions

  • Choroidal Neovascularization
  • Wet Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ICON-1 — BIOLOGICAL
    ICON-1 0.6 mg by intravitreal injection
  • aflibercept — BIOLOGICAL
    aflibercept 2 mg by intravitreal injection

Study Details

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.

Key Dates

First listed
Mar 2, 2018
Start date
Mar 26, 2018
Status verified
Nov 2020
Primary completion
Apr 25, 2019
Completion
Apr 25, 2019

Study Design

Enrollment
15 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ICON-1 maintenance therapy
    ICON-1 maintenance therapy after initial aflibercept treatment
  • Experimental: ICON-1 combination therapy
    ICON-1 combination therapy with aflibercept treatment

Primary Outcome Measure

Change in Choroidal Neovascularization (CNV) Over Time [ Time Frame: Month 9 ]

Locations (8)

FacilityCityStateZIPSite coordinators
Site 2Beverly HillsCalifornia90211-
Site 8Santa AnaCalifornia92705-
Site 7SyracuseNew York13224-
Site 3AshlandOregon97520-
Site 6PhiladelphiaPennsylvania19107-
Site 1AustinTexas78705-
Site 4McAllenTexas78503-
Site 5San AntonioTexas78240-

Related Studies